Clara Rubinstein, Gabriela Levitus, Carmen Vicien, Natalia Andrea Modena, Sandra Ruzal, Facundo Vesprini, Dalia Marcela Lewi, Cecilia Caminoa, Maria Fabiana Malacarne, Nerina Francescutti, Juan Ignacio Amaturo
{"title":"Genetically modified microorganisms for agricultural use: an opportunity for the advancement of risk assessment criteria in Argentina.","authors":"Clara Rubinstein, Gabriela Levitus, Carmen Vicien, Natalia Andrea Modena, Sandra Ruzal, Facundo Vesprini, Dalia Marcela Lewi, Cecilia Caminoa, Maria Fabiana Malacarne, Nerina Francescutti, Juan Ignacio Amaturo","doi":"10.3389/fbioe.2025.1612226","DOIUrl":null,"url":null,"abstract":"<p><p>The development and use of biologicals in agriculture is of growing interest globally. The potential of these tools to increase and protect yield complementing other tools has stimulated the interest of developers. Agricultural countries like Brazil and Argentina in Latin America have extensive experience with the use of biologicals for biocontrol and as seed inoculants. The last decade has seen the number of bio-based startups grow in the region, many of those dedicated to the development of microbial based bio-inputs. The potential for improving the efficacy and functionality of these products by means of gene technologies is very promising; however, the regulatory oversight of these innovations needs adaptation to become fit for purpose. The Biotechnology Working Group at ICCAS identified the need for a science-based discussion on this matter and considered alternatives to the current paradigm, developed over 30 years ago for transgenic plants.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"13 ","pages":"1612226"},"PeriodicalIF":4.8000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202534/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2025.1612226","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The development and use of biologicals in agriculture is of growing interest globally. The potential of these tools to increase and protect yield complementing other tools has stimulated the interest of developers. Agricultural countries like Brazil and Argentina in Latin America have extensive experience with the use of biologicals for biocontrol and as seed inoculants. The last decade has seen the number of bio-based startups grow in the region, many of those dedicated to the development of microbial based bio-inputs. The potential for improving the efficacy and functionality of these products by means of gene technologies is very promising; however, the regulatory oversight of these innovations needs adaptation to become fit for purpose. The Biotechnology Working Group at ICCAS identified the need for a science-based discussion on this matter and considered alternatives to the current paradigm, developed over 30 years ago for transgenic plants.
期刊介绍：
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
